Sydney Antibody Therapeutics

Conference

7th & 8th May 2025

Coming Soon

Main-Image001

Speakers

Meet our Speakers

2018 Nobel Prize Winner
Trinity College, Cambridge University

CEO of AbCellera

Senior Scientist - Twist Bioscience

local & international speakers

Georgina Clark

The ANZAC Research Institute

Peter Hudson

Avipep Therapeutics

Mark Hogarth

Burnet Institute

Michael Wheatcroft

Telix Pharmaceuticals

Patrick Schlegel

Biosceptre

Sheryl Van Nunen

Northern Beaches Hospital

Andrew Scott

Olivia Newton-John Cancer Research Institute

Henry Maun

Genentech

Daniel Scott

The Florey Institute and LASEREDD Therapeutics

Mihriban Tuna

Immutrin and Cambridge Innovation Capital

Rowena Bull

University of New South Wales

Stephen Mahler

Aegros

Anthony Doyle

Teva Pharmaceuticals

Louis Fabri

CSL

Mark Liddament

CSL

Imad Ajjawi

Absci

Venue

CONFERENCE

Join us at the N’Galawa Terrace in the Taronga Centre at Taronga Zoo

ACCOMMODATION

Stay in the city

Head over to the Zoo by ferry or a 20 minute taxi ride.

View ferry timetable

Stay at the zoo

Enjoy an overnight stay at Taronga Zoo Sydney for a truly unique and immersive experience amongst the wild.

Book with Taronga Zoo

Program

Day 1

7th May 2025

Day 2

8th May 2025

KEYNOTE

Streamlining development of next-gen t-cell engagers

Carl Hansen

SESSION ONE – DISCOVERY

Mapping antibody epitopes in hepatitis C and Covid-19 patients

Rowena Bull

Lentiviral-driven directed evolution of optimised GPCRs for antibody discovery

Daniel Scott

SESSION TWO – ONCOLOGY (I)

Antibody targeting of tumour cells and microenvironment

Andrew Scott

Bispecific antibodies in cancer immunotherapy – could they be the next big breakthrough?

Mihriban Tuna

SESSION THREE – DEVELOPMENT (I)

Project turbo: An accelerated development approach to early clinical development

Louis Fabri

Production of an anti-SARS-CoV-2 globulin from COVID-19 convalescent plasma by HaemaFrac® technology

Stephen Mahler

SESSION FOUR – DEVELOPMENT (II)

CSL's Innovative Clinical-Stage Antibody Pipeline: Leveraging external innovation and collaboration to improve patient outcomes

Mark Liddament

Harnessing the therapeutic potential of cytokines: reducing toxicity by specifically directing activity to target cell population by antibody-mediated delivery of attenuated cytokine

Anthony Doyle

KEYNOTE

Antibodies and antibody mimics

Greg Winter (Virtual)

SESSION FOUR – NOVEL TARGETS AND TECHNOLOGIES (I)

KEYNOTE

The Twist synthetic biology platform

Maxwell Stefan

Antibodies against alpha-galactose in allergy and xenotransplantation

Sheryl van Nunen

Stellabody® modification transforms effector function of therapeutic mAbs and Fc fusions

Bruce Wines

SESSION FIVE – NOVEL TARGETS AND TECHNOLOGIES (II)

Inhibition of tetrameric β-tryptase for severe asthma by mono- and bivalent antibodies with distinct allosteric mechanisms of action

Henry Maun

Anti-CD300f antibody drug conjugate facilitates a targeted conditioning regimen for allogeneic stem cell transplantation in AML

Georgina Clark

Antibody design using generative AI

Imad Ajjawi

SESSION SIX – ONCOLOGY (II)

Engineered Avibodies (enhanced Diabodies) precisely loaded with novel ADC payloads that surpass IgG-ADCs in cancer therapy

Peter Hudson

How antibodies can pave the way for CAR T cell therapy

Patrick Schlegel

Antibody-directed radiation (Theranostics)

Michael Wheatcroft

Sponsors

Organisers

Platinum Sponsors

DecodeTwist Logo
Sartorius Logo

Coffee Station Sponsor

Gold Sponsors

Silver Sponsors

sponsorship applications close friday 21st April

Take this unique opportunity to gain brand awareness and visibility within the Australian and International Antibody Therapeutic community